currie_mark_ironwood

Ironwood announces new president of R&D

pharmafile | February 13, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing Ironwood 

Ironwood Pharmaceuticals has announced the promotion of Mark Currie, to senior vice president, chief scientific officer, and president of research and development.

“Mark’s outstanding contributions to Ironwood, including his expertise, leadership and superb judgment, are invaluable as we move our R&D efforts forward, growing our active pipeline and expanding our development efforts globally on behalf of our shareholders and the patients we aim to serve,” said Peter Hecht, chief executive officer of Ironwood.

Dr Currie has led the company’s R&D efforts since he joined Ironwood in 2002 and previously served as senior vice president, R&D and CSO at the firm. Prior to that, he directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor.

Advertisement

Previously, Currie initiated, built, and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company.

Related Content

shutterstock_79370437

Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts

Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for …

astellas_japan_headquarters

Astellas and Ironwood release positive Phase 3 results for constipation drug

Astellas Pharma, a Tokyo-based pharmaceutical, and Ironwood Pharmaceuticals, based in Cambridge, Massachusetts, have announced positive …

ironwood_pharma

AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals

AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which …

The Gateway to Local Adoption Series

Latest content